Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | KMT2A rearrange |
Therapy | Azacitidine + JNJ-75276617 |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KMT2A rearrange | acute myeloid leukemia | predicted - sensitive | Azacitidine + JNJ-75276617 | Preclinical | Actionable | In a preclinical study, treatment with the combination of JNJ-75276617 and Vidaza (azacitidine) resulted in increased lifespan and improved survival in a mouse model of acute myeloid leukemia harboring a KMT2A rearrangement compared to treatment with Venclexta (venetoclax) plus Vidaza (azacitidine) (Blood (2023) 142 (Supplement 1): 4167). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
Preclinical Efficacy of the Menin-KMT2A Inhibitor JNJ-75276617 in Combination with Venetoclax and Azacitidine in AML | Full reference... |